Pricing

Y-mAbs Therapeutics Inc (YMAB)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Thomas Gad
Employees:
150
230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169
212-847-9841
Y-mAbs Therapeutics, Inc. focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer in the United States. The company is developing DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor. GD2-GD3 vaccine that is in Phase II clinical trial for the. treatment of Stage 4 high-risk neuroblastoma.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available